Eli Lilly & CompanyThe British NICE has defined the conditions for the reimbursement of Eli Lilly’s obesity blockbuster tirzepatide. This makes the UK the first country in which patients do not have to pay for the drug out of their own pocket.
Tag Archive for: obesity
Resalis Therapeutics srlAfter securing an equity investment from French pharma giant Sanofi, Italian gene therapy company Resalis Therapeutics srl has begun enrolling participants for a Phase I study of its obesity gene therapy, RES-010, which converts white adipocytes into brown adipocytes.
Novo NordiskNovo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist.
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038In both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity blockbuster.
Resalis/VimeoItalian obesity gene therapy developer Resalis Therapeutics srl has gained an equity investment from French pharma major Sanofi SA sufficient to finance its miRNA-22 antisense blocker RES-010 through Phase II proof-of-concept.
Hayo Therapeutics SASwiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions.
Confo Therapeutics NVBelgian GPCR specialist Confo Therapeutics NV has raised €60m in an Series B financing round led by Ackermans & van Haaren to advance clinical development of two clinical programmes and preclinical candidates to treat rare endocrine diseases and obesity.
Drug discovery CRO Evotec SE announced has entered into a partnership with Inserm, Lille University Hospital and Inserm Transfert to screen new biomarkers and targets in obesity and metabolic diseases.
Roche, Herzog&De MeuronObesity candidate CT-388, which Genentech added to Roche’s pipeline with the acquisition of Carmot Therapeutics, is at least not a disappointment, according to new trial data.
A German-Danish team has discovered that a truncated version of the enzyme adenlyate cyclase 3 can be targeted to transform fat-storing white adipocytes into fat-burning brown adipocytes.